hyoscine-n-butylbromide for Endometrial Neoplasms

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Endometrial Neoplasms+6 More
hyoscine-n-butylbromide - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial will use a novel, high-performance tracer to detect hormone-sensitive uterine and ovarian tumors using PET imaging. This could improve the whole-body assessment of those diseases and help clinicians choose the best course of therapy.

Eligible Conditions
  • Endometrial Neoplasms
  • Ovarian Cancer
  • Endometrial Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 48 months

48 months
Compare 4FMFES-PET with standard FDG-PET in gynaecological cancers.
Evaluate 4FMFES-PET diagnostic properties in endometrial and ovarian cancers
Use pharmaceutical intervention to slow down peristalsis to improve lower-abdomen 4FMFES-PET

Trial Safety

Safety Progress

1 of 3

Trial Design

3 Treatment Groups

Control group
1 of 3
Hyoscine-N-butylbromide
1 of 3
Loperamide
1 of 3

Active Control

Experimental Treatment

72 Total Participants · 3 Treatment Groups

Primary Treatment: hyoscine-n-butylbromide · No Placebo Group · Phase 1 & 2

Hyoscine-N-butylbromide
Drug
Experimental Group · 1 Intervention: hyoscine-n-butylbromide · Intervention Types: Drug
Loperamide
Drug
Experimental Group · 1 Intervention: Loperamide Pill · Intervention Types: Drug
Control groupNoIntervention Group · 1 Intervention: Control group · Intervention Types:
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Butylscopolamine
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 months

Who is running the clinical trial?

Université de SherbrookeOTHER
261 Previous Clinical Trials
67,695 Total Patients Enrolled
Centre de recherche du Centre hospitalier universitaire de SherbrookeLead Sponsor
51 Previous Clinical Trials
30,590 Total Patients Enrolled
Éric Turcotte, MDPrincipal InvestigatorUniversité de Sherbrooke

Eligibility Criteria

Age 18+ · Female Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a primary tumor that is more than 1 cm in size, and has spread to the lymph nodes.
You are a woman with recurrent endometrial or ovarian cancer and with a ER+ primary tumor.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: November 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.